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Abstract
Objectives: Apolipoproteins have recently been implicated in the etiology of Alzheimer’s disease (AD). In particular,
Apolipoprotein J (ApoJ or clusterin) has been proposed as a biomarker of the disease at the pre-dementia stage. We
examined a group of apolipoproteins, including ApoA1, ApoA2, ApoB, ApoC3, ApoE, ApoH and ApoJ, in the plasma of
a longitudinal community based cohort.
Methods: 664 subjects (257 with Mild Cognitive Impairment [MCI] and 407 with normal cognition), mean age 78 years, from
the Sydney Memory and Aging Study (MAS) were followed up over two years. Plasma apolipoprotein levels at baseline
(Wave 1) were measured using a multiplex bead fluorescence immunoassay technique.
Results: At Wave 1, MCI subjects had lower levels of ApoA1, ApoA2 and ApoH, and higher levels of ApoE and ApoJ, and
a higher ApoB/ApoA1 ratio. Carriers of the apolipoprotein E e4 allele had significantly lower levels of plasma ApoE, ApoC3
and ApoH and a significantly higher level of ApoB. Global cognitive scores were correlated positively with ApoH and
negatively with ApoJ levels. ApoJ and ApoE levels were correlated negatively with grey matter volume and positively with
cerebrospinal fluid (CSF) volume on MRI. Lower ApoA1, ApoA2 and ApoH levels, and higher ApoB/ApoA1 ratio, increased
the risk of cognitive decline over two years in cognitively normal individuals. ApoA1 was the most significant predictor of
decline. These associations remained after statistically controlling for lipid profile. Higher ApoJ levels predicted white matter
atrophy over two years.
Conclusions: Elderly individuals with MCI have abnormal apolipoprotein levels, which are related to cognitive function and
volumetric MRI measures cross-sectionally and are predictive of cognitive impairment in cognitively normal subjects.
ApoA1, ApoH and ApoJ are potential plasma biomarkers of cognitive decline in non-demented elderly individuals.
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Introduction
It is estimated that 35.6 million people worldwide currently
suffer from dementia [1]. Alzheimer’s disease (AD) is the most
common cause of dementia and AD pathogenesis may affect the
brains of patients for years or even decades before clinical
symptoms are fully expressed. Mild cognitive impairment (MCI)
has been proposed to describe the early phase of cognitive decline
that precedes dementia. MCI patients progress to AD, vascular
and other kinds of dementia [2]. Annual rates of conversion from
MCI to dementia are reported to range from 2.7% [3] to 10–15%
[4], [5]. People with MCI are more likely to develop AD than
cognitively normal individuals [6].
The etiology of sporadic AD is not well understood, and
vascular risk factors appear to play an important role [7]. A history
of vascular disease including heart disease and cerebrovascular
disease has a negative impact on cognition in old age [8]. High
serum total cholesterol at midlife is a risk factor for AD and other
dementia types in later life [9,10], and is also directly associated
with higher risk of dementia mortality [11]. Clinical and
epidemiological studies also support a strong relationship between
AD and cardiovascular disease (CVD) risk factors such as high
density lipoprotein (HDL) levels, low density lipoprotein (LDL)
levels and the presence of atherosclerosis and hypertension [12].
Even though there is no consistent evidence for the role of
cholesterol lowering agents in AD treatment, some studies suggest
that they reduce the incidence of AD [13,14].
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e34078Apolipoproteins (Apo) are a group of proteins related to
cholesterol and lipid metabolism [15,16], and recent findings
indicate that apolipoproteins might also be involved in neurode-
generative processes [17,18,19,20] (figure 1). A transgenic mouse
model overexpressing amyloid precursor protein (APP) and
presenilin 1 (PS1) was found to have increased plasma ApoJ
(clusterin) levels, as well as amyloid and ApoJ co-localization in
plaques [20]. ApoA1 and ApoA2 are major components of HDL,
and are involved in transport of cholesterol to the liver [15]. A
triple transgenic mouse model (overexpressing mutant forms of
APP, PS1 and ApoA1) showed that overexpression of ApoA1
prevented the development of age-related learning and memory
deficits despite continued Ab deposition [18]. Furthermore,
Kawano et al found lower plasma levels of ApoA1 and ApoA2 in
Japanese patients with late-onset non-familial AD [21]. Bereczki et
al showed that overexpression of human ApoB in the serum of
transgenic mice caused the formation of amyloid plaques and
extensive neuronal death [22] and two studies have found
significantly higher levels of ApoB in the serum of AD subjects
[23,24]. Furthermore, Scacchi et al [25] have demonstrated a link
between the APOB EcoR1 R+R genotype and higher total
cholesterol and LDL cholesterol relative to R+R+ homozygotes.
However, apart from this handful of disparate studies, little is
known about the role of ApoB at preclinical stages of dementia
such as MCI. ApoC3 is a component of very low density
lipoprotein (VLDL) and delays the breakdown of triglycerides,
leading to development of hypertriglyceridemia and increased risk
of atherosclerosis [26].
The APOE e4 allele is a significant genetic risk factor for
sporadic AD [27,28]. In the periphery, ApoE aids transport of
triglycerides, phospholipid, cholesterol esters and cholesterol into
cells [16]. However, the literature is conflicted on the direction of
change in levels of plasma ApoE protein in AD as well as the effect
of the APOE polymorphism on protein levels. A few studies have
reported significantly lower ApoE protein in patients with AD
[29,30,31,32,33], while several other studies show increased levels
[34,35,36]. Similarly the literature on the relationship between
APOE e4 allele and plasma ApoE levels is limited and controversial
with some studies showing increased apoE protein levels in APOE
e4 allele carriers [31,33,35], while other studies observe the
opposite [29,30]. Furthermore, there is evidence in the literature
that the APOE polymorphism may affect the expression level of
other apolipoproteins, such as ApoB, as well [16], however
fleetingly little work has been done on this topic. Consequently
additional studies are needed to help resolve the question of what
role, if any, genetic variance has on plasma apolipoprotein levels.
ApoH is involved in diverse physiological processes, including
lipid metabolism [37], however, little is known about the role if
any that this protein may play in MCI or dementia. Only a single
study is available, showing elevated ApoH in the CSF of several
dementia subtypes [38]. In recent studies, allele variants of APOJ
(CLU,clusterin) were shown to be associated with increased risk of
AD [39,40]. Higher plasma ApoJ levels are reported to be
associated with atrophy of the entorhinal cortex and faster
cognitive decline in AD [20], as well as involved in clearance of
amyloid beta (Ab) [41].
Therefore, these seven apolipoproteins, ApoA1, ApoA2, ApoB,
ApoC3, ApoE, ApoH and ApoJ, were chosen for the analysis of
plasma in MCI and cognitively normal subjects in a community
based study. The aims of the present study were, to determine if
plasma apolipoproteins are abnormal in MCI subjects at an early
stage of cognitive decline, and to establish if baseline apolipopro-
tein levels are predictive of cognitive impairment in cognitively
normal subjects over a two year period. Finally, we wished to
examine the effect of APOE e4 allele on plasma ApoE levels,
correlations of apolipoproteins with age and with lipid profiles,
including total cholesterol, HDL-cholesterol, LDL-cholesterol and
triglycerides, and the association of lipid profile with cognitive
decline. We tested the hypothesis that apolipoproteins involved in
the transportation of cholesterol and triglycerides are risk factors
for cognitive impairment, and cognitive decline in elderly non–
demented individuals.
Methods
Ethics Statement
The procedures of this study were approved by Human
Research Ethics Committee of the University of New South
Wales on human experimentation, and written informed consent
was obtained from all participants involved in this study.
Figure 1. Potential pathophysiological mechanisms involving apolipoproteins in Alzheimer’s disease. Literature evidence: *, Katzav,
Faust-Socher et al. 2011; George and Erkan 2009. **, Lewis, Cao et al. 2010; Roher, Maarouf et al. 2009; Martins, Berger et al. 2009; Bereczki, Bernat
et al. 2008.
doi:10.1371/journal.pone.0034078.g001
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Plasma samples were from Wave 1 (baseline) of the Sydney
Memory and Ageing study (MAS), described in detail in a pre-
viously published paper [42], which comprised a cohort of non-
demented elderly individuals drawn randomly from the commu-
nity through the electoral roll. Individuals aged 70–90 years
(n=8914) were initially invited to participate MAS and 7142
either did not respond to the letter or declined to participate [42].
Of the remaining 1772 contacted by telephone to confirm
eligibility, 735 were either ineligible or declined after further
information about the study [42]. The final sample comprised
1037 individuals who received detailed Wave 1 assessment
documentation [42]. Of these, 943 provided a blood sample,
and magnetic resonance imaging (MRI) brain scans were
performed on 544 individuals.
Participants were excluded if they had a previous diagnosis of
dementia, psychotic symptoms or a diagnosis of schizophrenia or
bipolar disorder, multiple sclerosis, motor neuron disease, de-
velopmental disability, progressive malignancy (active cancer or
receiving treatment for cancer, other than prostate non-metasta-
sized, and skin cancer), or if they had medical or psychological
conditions that may have prevented them from completing
assessments. Participants were excluded if they had a Mini-Mental
State Examination (MMSE) [43] score of ,24 adjusted for age,
education and non-English speaking background [44] at study
entry, or if they received a diagnosis of dementia after
comprehensive assessment.
Participants received a detailed neuropsychological evaluation,
and a subset had MRI brain scans at Waves 1 and 2, two years
apart. A subgroup of 664 subjects was included in this study, of
which the Wave 1 characteristics are shown in table 1. Blood
samples were obtained via venipuncture after overnight fasting,
and transferred into ethylenediaminetetraacetic acid (EDTA)
coated tubes. Blood samples were centrifuged (1500 g) at room
temperature for 15 minutes. Supernatant plasma was collected
and aliquoted into polypropylene tubes. Plasma samples were
stored at -80 uC, and thawed immediately before assay.
Clinical Evaluation
Table S1 in the supplementary data lists cognitive domains that
each neuropsychological test was allocated to for the purpose of
calculating domain scores. These domains were attention/
processing speed, memory, verbal memory, language, visuo-spatial
ability and executive function, as detailed in previously published
article [42]. Domain scores were formed as the average of the Z-
scores of their component tests.
The diagnosis of MCI was based on international consensus
criteria [45], as follows: (a) complaint of decline in memory or
other cognitive function which may be self- or informant-reported;
(b) cognitive impairment on objective testing, i.e. not normal for
age as determined by performance on at least one test measure 1.5
SDs or more below published normative values (or comparable
standardized score compared to age and/or education-matched
samples); (c) participants did not have a pre-existing diagnosis of
dementia on entry to the study, had an adjusted MMSE score of
$24 and did not meet DSM-IV criteria [46] for possible or
probable dementia; (d) essentially normal function or minimal
impairment in instrumental activities of daily living (IADLs)
defined by a total average score ,3.0 on the informant rated
Bayer Activities of Daily Living Scale (B-ADL) [47].
Clinical Dementia Rating (CDR) [48] scores were obtained on
all participants for both Waves. CDR of 0 indicated normal
whereas CDR 0.5 and CDR 1 indicated cognitive impairment
(MCI or very mild dementia) and mild AD dementia, re-
spectively [4].
APOE Genotyping
Genomic DNA was extracted from peripheral blood leukocytes
or saliva samples using standard methods. Genotyping of two
apolipoprotein E gene (APOE) single nucleotide polymorphisms
(SNPs) was undertaken to determine the APOE genotype, which is
comprised of three alleles (e2, e3, e4). Two separate Taqman
genotyping assays (Applied Biosystems Inc. [ABI], Foster City,
CA) were used to genotype the two APOE SNPs, NCBI rs7412 and
NCBI rs429358. The SNP NCBI rs7412 distinguishes the e2 allele
from the e3/e4 alleles whilst the SNP NCBI rs429358 differ-
Table 1. Participant Wave 1 demographic information and apolipoprotein levels.
Normal n=407 MCI n=257 p P(FDR corrected)
Age, years 77.964.5 78.864.7 0.01 –––
Male, n, % 175(43%) 126 (49%) 0.13 –––
Years of education 11.663.5 11.363.4 0.30 –––
APOE e4 carrier, n, % 84 (20.6%) 72 (28.0%) 0.03 –––
Hypolipidaemic medications, n,% 205 (49.9%) 124(47.5%) 0.55
ApoA1 (mg/ml) 2.9761.28 2.7061.12 0.01 0.013
ApoA2 (mg/ml) 158.63645.78 148.50647.63 0.003 0.008
ApoB (mg/ml) 1.8660.53 1.9860.68 0.07 0.08
ApoC3 (mg/ml) 64.04623.59 60.12624.13 0.08 0.08
ApoE (mg/ml) 36.30620.40 39.86622.00 0.01 0.013
ApoH (mg/ml) 171.40643.07 156.44645.10 0.00002 0.00008
ApoJ (mg/ml) 108.97627.43 119.98633.03 0.000006 0.00008
ApoB/ApoA1 0.7360.38 0.8660.47 0.005 0.01
Data are presented as mean6SD.
Covariates in ANCOVA for effects of apolipoproteins: age, sex, years of education, APOE e4 carrier status, hypolipidaemic medications.
doi:10.1371/journal.pone.0034078.t001
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indicates carrying at least one APOE e4 allele.
Quantification of Apolipoproteins in Wave 1 Plasma
Samples
Plasma apolipoprotein concentrations were assayed using
multiplex fluorescent immunoassay kits (WideScreen
TM Human
CVD Panel 1; Novagen, EMD Chemicals Inc, WI). The xMAP
platform used here was based on the Rules Based Medicine (RBM)
fluorescent beads and antibody pairs. These are sensitive, specific
and widely used reagents, sourced by numerous manufacturers
and data collected using xMAP multiplex beads are widely
reported in the literature in studies where simultaneous assay of
multiple plasma proteins, including apolipoproteins, are per-
formed. Some recent examples of published work which has made
use of human xMAP multiplex technology include; [38,50,51].
Plasma samples (5 mL) were diluted 1:2500 in dilution buffer, and
manufacturer’s instructions were followed, with the additional
precaution of handling the fluorescent beads in a darkened room.
Samples were run in duplicate using a Bioplex system (Luminex
100, BioRad, Hercules, CA) Bio-Plex Manager 4.0 using a 5
parameter logistic regression model. The average intra- and inter-
assay CVs were ,7.0% and ,17.9%, respectively. The range of
standard concentrations is provided in (Table S2).
Quantification of Lipid Profile in Wave 1 Plasma Samples
Total cholesterol, HDL-cholesterol and triglycerides were
measured in heparin plasma aliquots using a Beckman LX20
Analyzer using a timed-endpoint method (Fullerton, CA). This
direct HDL-cholesterol method requires no off-line pre-treatment
steps. LDL-cholesterol was estimated using the Friedewald
equation (LDL-cholesterol=total cholesterol - HDL-cholesterol -
triglycerides/2.2). These assays were conducted in an independent
laboratory of South Eastern Area Laboratory Services.
Acquisition of Neuroimaging Data
All participants were invited to undergo an MRI scan, and those
who agreed were screened for contra-indications (pacemaker,
metallic implant or foreign bodies, cochlear implants, ferromag-
netic homeostatic clips, claustrophobia). A subgroup (n=376) was
included in this study at Wave 1, and 282 subjects at Wave 2.
Subjects were scanned using a Philips 3 T Intera Quasar scanner
(Philips Medical Systems, Best, Netherlands). The main parame-
ters for T1-weighted 3D structural MRI were: TR=6.39 ms,
TE=2.9 ms, flip angle=8u, matrix size=2566256,
FOV=25662566190, and slice thickness=1 mm with no gap
between; yielding 16161 mm3 isotropic voxels. The T2-weighted
fluid attenuated inversion recovery (FLAIR) sequence was
acquired with TR=10000 ms, TE=110 ms, TI=2800; matrix
size=5126512; slice thickness=3.5 mm with no gap between
slices, yielding spatial resolution of 0.48860.48863.5 mm3/voxel.
Statistical Analysis
All statistical analyses were performed using SPSS Version 18.0
(SPSS Inc., Chicago, IL). Differences between normal and MCI
groups on categorical variables (sex and APOE e4 status) were
evaluated using Chi squared tests, and t-tests were used for
examining differences between these groups on age and years of
education. Group differences between apolipoprotein levels were
assessed using analysis of covariance (ANCOVA), with age, sex,
years of education and APOE e4 status entered as covariates. For
these analyses, the distributions of apolipoprotein levels were
inspected and, when necessary, transformed to more closely
approximate the normal distribution. As a result, ApoA1, ApoA2,
ApoE, ApoJ and ApoB/ApoA1 ratio were log transformed and
ApoB, ApoC3 and ApoH levels were square-root transformed.
Partial correlations were used to examine the relationships of the
apolipoproteins with lipid levels, cognitive domain composite
scores and brain volumetric measures. Control variables were age
and sex for correlations with lipids; age, sex, years of education
and APOE e4 status for correlations with neuropsychological
measures; and age, sex and intracranial volume (ICV) for
correlations with brain volumes. An alternative approach was to
apply a non-parametric test to the raw (non-transformed) data.
Consequently we also checked the data using the Spearman Rank
Correlation, however the main results did not change.
To assess if plasma apolipoproteins levels predicted cognitive
decline in cognitively normal participants, logistic regression
analysis was performed, using only those participants with
a CDR=0 at Wave 1, and a CDR of .0 (versus CDR=0) at
Wave 2 as the dependent variable. We used the z-scores of
apolipoproteins as independent variables, so that the odds ratios
(ORs) reflect the ratio of odds when values of apolipoproteins
increase by one standard deviation (SD). Age, sex, years of
education and APOE e4 status were included in this analysis as
control variables. Also included as a control variable was a CVD
risk index which we calculated based on the regression model of
the Framingham Heart Study [52]. This index used the following
MAS Wave 1 variables: current smoking status, diabetic status,
systolic blood pressure, total cholesterol level, HDL level and
current use of antihypertensive medication. When blood analyses
were unavailable (n=3), Body Mass Index was used instead of
cholesterol and HDL data.
Linear regression models were used to examine whether Wave 1
apolipoprotein levels were associated with brain volumetric
changes from Wave 1 to Wave 2, including changes in CSF
volume, grey matter, white matter and hippocampal volume, and
brain atrophy between the two waves. The brain atrophy measure
during follow-up was calculated as the changes of brain volume
(sum of grey matter and white matter volumes) divided by ICV.
Transformed apolipoprotein levels were used as independent
variables and age and sex were covariates. ICV was also used as
a control variable for brain volume variables, except for the
atrophy measure.
P-values, corrected for multiple testing using the false discovery
rate (FDR) method, were used when evaluating the statistical
significance of results [53]. P values in the ANCOVA, partial
correlation and logistic regression were corrected by FDR. After
FDR correction, P,0.05 was considered as significant level.
Results
Demographic Characteristics and Apolipoprotein Levels
at Wave 1
The Wave 1 demographic information on cognitively normal
and MCI participants is shown in table 1. MCI subjects were
slightly older and more likely to be APOE e4 carriers. No statistical
differences were noted in gender and years of education between
MCI and cognitively normal subjects. ApoE and ApoJ had weak
but significantly positive correlations with age at Wave 1 (ApoE:
r=0.11, p=0.003; ApoJ: r=0.09, p=0.02). We studied the
association of all seven apolipoproteins assayed in this study with
APOE e4 genotype (table 2). After adjusting for age and gender,
APOE e4 homozygous carriers have significantly lower plasma
ApoE level than non APOE e4 carriers or APOE e4 heterozygote
carriers. ApoE levels are also positively correlated with age.
Furthermore, plasma levels of ApoB are significantly increased
Plasma Apolipoprotein and Cognitive Decline
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carriers. Plasma levels of ApoH are close to significantly decreased
(p=0.08) in APOE e4 heterozygote carriers, and are in fact
significantly decreased relative to non-carriers when the data for
heterozygotes and homozygotes are pooled (table 2).
After adjusting the p values using the FDR method, MCI
subjects had lower levels of ApoA1 (F=6.34, p=0.013), ApoA2
(F=9.20, p=0.008) and ApoH (F=18.78, p=0.00008), and
higher levels of ApoE (F=6.06, p=0.013), ApoJ (F=20.76,
p=0.00008) and ApoB/ApoA1 (F=8.10, p=0.01).
Partial Correlations Amongst Apolipoproteins and with
Lipid Levels
Most correlations between apolipoproteins were weak to
moderate (table 2; 0.10,r,0.50, p,0.001). Several correlations
(those between ApoA1 and ApoA2, ApoA2 and ApoC3, ApoA2
and ApoH, ApoA2 and ApoB/ApoA1) were relatively strong with
values greater than 0.50 (table 3). Correlations between apolipo-
proteins, and lipid levels varied from near zero to a moderately
high value of 0.60 between ApoA1 and HDL-cholesterol, and 0.53
between ApoE and triglycerides (p,0.001) (table 3). No significant
correlations were shown between ApoJ and total cholesterol,
HDL-cholesterol, LDL-cholesterol or triglycerides (p.0.05)
(table 3).
Plasma Apolipoproteins and Neuropsychological
Performance at Wave 1
Table 4 shows the partial correlation of plasma apolipoproteins
with global cognitive and cognitive domain scores at Wave 1.
ApoH levels were positively correlated with global cognition
(r=0.15, p=0.001), attention/processing speed (r=0.11,
p=0.04) and executive function (r=0.15, p=0.006). ApoJ levels
were negatively correlated with scores of global cognition
(r=20.13, p=0.04) and attention/processing speed (r=20.11,
p=0.04). ApoE levels were negatively correlated with total
memory (r=20.11, p=0.04) and verbal memory domain scores
(r=20.11, p=0.04). ApoA2 levels were positively correlated only
with attention/processing speed (r=0.12, p=0.04). Though the
correlations at Wave 1 were modest, they remained significant
after adjusting for FDR. Scatter plots of significant correlations are
presented in (figure S1, S2, S3, S4, S5, S6, S7).
Plasma Apolipoproteins and Brain Volumes at Wave 1
Wave 1 apolipoprotein levels were correlated with grey matter
and CSF volume (table 5). ApoC3, ApoE and ApoJ were
negatively correlated with grey matter volume (ApoC3:
r=20.14, p=0.038; ApoE: r=20.14, p=0.038; ApoJ:
r=20.15, p=0.036) and positively correlated with CSF volume
(ApoE: r=0.16, p=0.036; ApoJ: r=0.14, p=0.038). The ApoB/
ApoA1 ratio was also negatively correlated with hippocampal
volume (r=20.13, p=0.04). These correlations are modest but
statistically significant. Scatter plots of significant correlations are
presented in (figure S8, S9, S10, S11, S12, S13).
Apolipoprotein Levels to Predict Future Cognitive
Decline
We investigated if apolipoprotein levels at Wave 1 could predict
conversion from cognitively normal (CDR=0) at Wave 1 to
cognitively impaired (CDR .0) at Wave 2. For this analysis, 517
participants had a CDR=0 at Wave 1 and of these 149
participants had a CDR greater than 0 at Wave 2. Individuals
who went from CDR 0 to CDR .0 were classified as converters, and
those remaining CDR 0 at Wave 2 were considered nonconverters.
Group characteristics are described in table 6. The converting rate
to CDR cognitively impaired is 14.41% annually.
Table 7 shows the results of a series of logistic regression
analyses predicting cognitive decline with conversion from
CDR=0 to CDR .0, with each apolipoprotein entered singly
into each model together with control variables age, sex, years of
education and APOE e4 carrier status. Results are also shown for
a second series of analyses that also included the CVD risk index
as an additional control variable. This revealed that ApoA1,
ApoA2, ApoH and ApoB/ApoA1 ratio significantly predicted
conversion, both with and without the CVD risk index being
included in the models. A decrease of one standard deviation of
ApoA1, ApoA2, ApoH and an increase of one standard deviation
of ApoB/ApoA1 increased the risk of conversion to CDR .0
(ApoA1: OR=0.65, P=0.016; ApoA2: OR=0.76, P=0.04;
ApoH: OR=0.77, P=0.04; ApoB/ApoA1: OR=1.46,
P=0.04). In summary, participants with lower ApoA1, ApoA2,
ApoH levels or higher ApoB/ApoA1, at Wave 1 had a higher risk
of future cognitive decline.
Table 2. Apolipoprotein levels in different APOE e4 carrier groups.
Non APOE e4 carrier
APOE e4 heterozygote
carrier
APOE e4 homozygous
carriers F p
N 508 144 12
ApoA1 mg/ml 2.8661.22 2.9161.26 2.6461.21 0.62 0.54
ApoA2 mg/ml 155.13647.29 151.95643.64 170.27658.37 0.70 0.50
ApoB mg/ml 1.8660.59 2.0460.62* 2.1060.31 5.11 0.006
ApoC3 mg/ml 64.04624.44 57.80621.11 54.88622.76 4.31 0.01
ApoE mg/ml 41.16621.44 26.94614.83** 19.06617.54**1 56.44 ,0.0005
ApoH mg/ml 167.66644.78 159.95642.87 147.00641.50 2.56 0.08
#
ApoJ mg/ml 113.64630.62 111.76628.33 113.66634.88 0.07 0.94
Statistics details: ANCOVA, Post-hoc: Bon Ferroni Covariates: age, sex.
*Compared to nonAPOE e4 carrier, p,0.05, **Compared to nonAPOE e4 carrier, p,0.0005.
1Compared to APOE e4 heterozygote carrier, p,0.0005.
#When heterozygous and homozygous carriers are pooled and compared with non APOE e4 carriers the ApoH values are statistically significant (n=156,
mean=158.95642.78, F=4.23, p=0.04). Pooling of data from heterozygous and homozygous carriers makes no difference to the statistical outcomes for any of the
other apolipoproteins, though the significant p values all become even slightly lower.
doi:10.1371/journal.pone.0034078.t002
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predictive value, the z-scores of all apolipoprotein measures were
entered together into a stepwise logistic regression (probability of F
for entry=0.05, and for removal=0.10), while adjusting for age,
sex, years of education, APOE e4 carrier status and CVD risk
index. Only ApoA1 showed a statistically significant effect on
cognitive decline from CDR=0 to CDR .0 after controlling for
the effects of the other apolipoproteins, and also age, sex, years of
education, APOE e4 carrier status and CVD risk index
(OR=0.63, 95%CI=0.48–0.84, P=0.001).
Relationship of Apolipoproteins with Brain Volume
Changes During Follow-up
With regard to the relationship between apolipoproteins and
brain neuroimaging changes, a slightly different pattern emerged.
For this analysis, 232 participants had neuroimaging data for both
waves. Linear regression models showed that increased ApoC3
levels were associated with a decrease in grey matter volume
(b=0.19, p=0.04), and increased ApoJ levels were associated with
a decrease in white matter volume (b=0.16, p=0.03) after two
years follow-up. Lower ApoA1 levels showed a weak but not
significant association with an increase in brain atrophy
(b=20.15, p=0.09). There were no associations between
apolipoprotein levels and increase in CSF volume or decrease in
hippocampus volume.
Lipid Profile and Cognitive Decline
The lipid profiles at Wave 1 were analysed to investigate if they
could predict conversion from cognitively normal (CDR=0) at
Wave 1 to cognitively impaired (CDR.0) at Wave 2. However,
none of the measures examined was associated with cognitive
impairment during follow-up; total cholesterol (OR=1.06,
p=0.94), HDL-cholesterol (OR=0.87, p=0.71), LDL-cholesterol
(OR=0.95, p=0.95) and triglycerides (OR=1.02, p=0.95).
Furthermore, including lipid profile as covariates did not affect
the ability of ApoA1, ApoA2 and ApoH levels and ApoB/ApoA1
ratio to predict cognitive impairment (table 6).
Discussion
In this study, we report for the first time detailed measurements
of multiple apolipoproteins in the plasma of elderly non-demented
subjects, and relate them to cognition. Our salient findings are that
MCI subjects at Wave 1 had lower levels of ApoA1, ApoA2, ApoH
and higher levels of ApoE, ApoJ and the ApoB/ApoA1 ratio.
Table 3. Partial correlations between apolipoproteins and lipid profiles.
ApoA1 ApoA2 ApoB ApoC3 ApoE ApoH ApoJ
ApoB/
ApoA1
ApoA1 – 0.60*** 0.01 0.39*** 20.05 0.35*** 0.16*** –
ApoA2 0.60*** – –0.04 0.57*** 0.09 0.50*** 0.23*** –0.50***
ApoB 0.01 20.04 – –0.08 0.05 20.10 0.23*** –
ApoC3 0.39*** 0.57*** –0.08 – 0.43*** 0.47*** 0.32*** –0.36***
ApoE 20.05 0.09 0.05 0.43*** – 0.25*** 0.36*** 0.05
ApoH 0.35*** 0.50*** 20.10 0.47*** 0.25*** – 0.30*** 20.34***
ApoJ 0.16*** 0.23*** 0.23*** 0.32*** 0.36*** 0.30*** – 20.01
ApoB/ApoA1 – 20.50*** – 20.36*** 0.05 20.34*** 20.01 –
HDL-cholesterol 0.60*** 0.22*** 20.001 0.13** 20.24*** 0.03 0.01 20.48***
LDL-cholesterol 0.01 0.07 0.29*** 0.08 0.06 0.06 0.03 0.16***
Total cholesterol 0.24*** 0.18*** 0.25*** 0.28*** 0.10* 0.11** 0.05 20.04
Triglycerides 20.22*** 0.06 20.02 0.49*** 0.53*** 0.19*** 0.08 0.16***
*p,0.05, **p,0.01, *** p,0.001(FDR corrected p values) Covariates: age, sex.
doi:10.1371/journal.pone.0034078.t003
Table 4. Partial correlations between apolipoprotein levels and global cognition/cognitive domain composite scores at Wave 1.
ApoA1 ApoA2 ApoB ApoC3 ApoE ApoH ApoJ ApoB/ApoA1
Global cognition r 0.04 0.07 20.06 0.02 20.07 0.15** 20.13* 20.05
Attention/processing speed r 0.07 0.12* 20.05 0.04 20.05 0.11* 20.11* 20.05
Memory r 0.01 0.03 20.03 20.04 20.11* 0.09 20.09 20.03
Verbal memory r 0.01 0.01 20.02 20.05 20.11* 0.08 20.07 20.03
Language r 20.01 0.02 20.07 0.003 20.009 0.09 20.06 20.03
Visuo-spatial r 0.01 0.03 20.01 20.007 20.05 0.07 20.07 20.01
Executive function r 0.06 0.05 20.03 0.02 20.07 0.15** 20.04 20.04
Subject numbers, n=657.
*p,0.05; **p,0.01 (FDR corrected p values, see text).
Covariates: age, sex, years of education, APOE e4 carrier status.
doi:10.1371/journal.pone.0034078.t004
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ward trends in APOE e4 allele carriers, whereas ApoB levels are
significantly increased in e4 carriers. Two years later, lower
ApoA1, ApoA2, ApoH levels and higher ApoB/ApoA1 ratio were
associated with cognitive decline in cognitively normal participants
after adjusting for age, sex, years of education, APOE e4 carrier
status and CVD risk index (See the summary in table 8).
Furthermore, lipid profile was not related with cognitive decline,
and did not affect the association of apolipoproteins with cognitive
impairment.
Our results therefore indicate that apolipoproteins are associ-
ated with cognitive decline independently of the effect of lipid
profile. The pathomechanisms underlying this relationship still
remain unclear. A few clinical studies have revealed that some
apolipoproteins are deregulated in AD patients [20,54], and work
on transgenic animal models suggests that some apolipoproteins
have a role in processing of amyloid precursor protein (APP), Ab
metabolism and neurodegenerative processes [18,22,41] (figure 1).
The relationship between cognition and individual apolipoproteins
is outlined in the following sections as it relates to the findings of
this study.
ApoA1, ApoB and Cognitive Decline
In this study, ApoA1 concentration was lower in MCI, and a low
level of ApoA1 was the strongest risk factor of cognitive decline in
comparison with other apolipoproteins. These observations are
consistent with published studies, which have shown a marked
decrease of ApoA1 levels in AD plasma and serum [21,55] and
demonstrated that decreased serum ApoA1 concentrations were
highly correlated with the severity of AD [56]. Further, ApoA1 in
CSF is significantly decreased in autopsy-confirmed AD patients
[57]. Interestingly, a triple transgenic mouse model over-expres-
sing mutant forms of APP, presenilin 1 and ApoA1 showed that
over-expression of ApoA1 prevented the development of age-
related learning and memory deficits despite continued Ab
deposition [18].
ApoA1 and ApoA2 are the principal apolipoproteins in HDL,
and are responsible for the reverse transport of cholesterol,
a process that removes excess cholesterol from peripheral tissues to
the liver for excretion [58]. ApoA1 is also believed to be a more
reliable parameter for measuring HDL than cholesterol content
since it is not subject to variation [15]. ApoB represents most of the
protein content in LDL and is also present in intermediate-density
lipoproteins (IDL) and VLDL, and is involved in the transport of
cholesterol to peripheral tissues. The ApoB/ApoA1 ratio reflects
the balance between two opposite processes, and is a valuable
indicator of CVD risk factors [15]. While, the roles of ApoA1 and
ApoB in the periphery have been studied extensively, their
functions in the central nervous system and memory function are
not fully understood.
ApoB has been found to be increased in AD plasma [23] and
serum [59], and our cross-sectional results are consistent with these
studies. ApoB in AD serum is correlated with Ab levels in brain
[59]. ApoB is not normally found in CSF [17]. However, by using
3-dimensional immunomicroscopy, plasma ApoB was found to be
co-localised with cerebral Ab in plaques in a transgenic mouse AD
model and plaque abundance was positively correlated with ApoB
[17,60]. A compromised blood brain barrier (BBB), which occurs
as part of AD pathology, may allow peripheral ApoB into the
brain which may then contribute to further pathology [61]. Over-
expression of ApoB in transgenic mice led to significant changes in
the cerebral protein profile and triggered apoptosis and neurode-
generation in the brain [22].
ApoE and Cognitive Decline
The results in the literature on ApoE levels in AD are
inconsistent. Darreh-Shori et al reported an APOE e4 gene-dose
dependent increase in the expression of ApoE in CSF and plasma
of AD patients, with the e4 homozygotes having about two-fold
Table 5. Partial correlation between apolipoprotein levels and brain volumes at Wave 1.
ApoA1 ApoA2 ApoB ApoC3 ApoE ApoH ApoJ ApoB/ApoA1
Grey matter r 20.01 20.08 20.03 –0.14* 20.14* 20.06 20.10* 20.07
White matter r 0.08 0.03 0.003 –0.02 20.05 0.01 20.01 20.05
CSF volume r 20.03 0.05 0.02 0.11 0.16* 0.05 0.14* 0.08
Hippocampus r 0.08 0.05 20.06 –0.03 –0.02 0.01 20.03 20.13*
Subject numbers, n=377.
*p,0.05 (FDR corrected p values, see text).
Covariates: age, sex, intracranial volume.
doi:10.1371/journal.pone.0034078.t005
Table 6. Demographic characteristics of nonconverters and converters at Wave 1.
Nonconverters (Wave 2 CDR=0) Converters (Wave 2 CDR .0) p
N 368 149
Age, mean(SD),y 77.364.1 79.264.7 ,0.0001
Male, n,% 140, 38% 85, 43% ,0.0001
Years of education 11.863.4 10.763.4 0.001
APOE e4 carrier, n, % 65, 17.9% 42, 28.6% 0.007
MMSE score, mean(SD) 28.561.2 27.861.4 ,0.0001
doi:10.1371/journal.pone.0034078.t006
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Australian Imaging, Biomarkers and Lifestyle (AIBL) study showed
that ApoE levels were significantly lower in patients with AD and
ApoE levels were significantly lower in e4 homozygous individuals
[29]. Other studies have also reported lower ApoE levels in AD
[30,31]. Lower serum ApoE levels were found in carriers of the
APOE e4 allele in another study [32]. Further investigations,
particularly long term longitudinal studies, are necessary to
establish if ApoE levels are potential plasma biomarkers of
cognitive decline, MCI or AD. Our data showed that ApoE levels
were significantly higher in the MCI group, and APOE e4
homozygous carriers had significantly lower ApoE level than
APOE e4 non-carriers and APOE e4 heterozygote carriers.
However, baseline ApoE levels were not associated with cognitive
decline after 2 year follow-up in this study.
The apparent inconsistencies in the published literature on
ApoE levels in AD or MCI may be due to multiple differences
between studies, including; (1) the sample, which can be CSF,
serum, plasma, urine or tissue (2) experimental design (i.e., cross-
sectional or longitudinal), (3) subject numbers, which can vary
from a handful of individuals to many 100’s if not 1000’s of
subjects, (4) methodological differences in the assay procedure
which may affect sensitivity or recovery. As an example the
detergent concentration in the dilution buffer may cause variation
of ApoE levels measured in different studies. Furthermore, as
a lipophilic protein, ApoE may be adsorbed to labware during
sample handling, possibly resulting in falsely low ApoE values [33].
Standardisation of sample handling protocols would certainly
improve consistency of outcomes between laboratories. However
some apparent discrepancies between different laboratories may in
fact reflect real differences in expression of proteins between
different locations within the body, or in trends over the course of
disease. For example there may be disease related differences in
the expression of apolipoproteins in CSF relative to plasma or
serum, due to such factors as a compromised BBB, other vascular
disruptions such as cerebral amyloid angiopathy, or protein
sequestration processes such as plaque deposition. Similarly,
protein concentrations may vary over time and may also be
differentially expressed in disease vs normal aging, which is why it
is important to collect longitudinal as well as cross-sectional data,
and to explore changes in prodromal conditions such as MCI and
well as at more advanced stages of dementia.
Table 7. Logistic regression analyses for the prediction of conversion from CDR 0 at Wave 1 to CDR .0 at Wave 2 from Wave 1
plasma apolipoprotein levels.
Models without CVD risk index included
as a control variable
Models with CVD risk index included as
a control variable
Models with CH, TG, HDL,LDL included
as control varaible
OR 95%CI Wald P p (FDR ) OR 95%CI Wald p P (FDR) OR 95%CI Wald p P (FDR)
ApoA1 0.61 0.46–0.80 12.82 0.0003 0.0024 0.65 0.49–0.86 9.18 0.002 0.016 0.56 0.41–0.78 11.98 0.001 0.008
ApoA2 0.73 0.58–0.91 7.61 0.006 0.016 0.76 0.61–0.96 5.27 0.022 0.04 0.72 0.57–0.91 7.45 0.006 0.016
ApoB 1.17 0.93–1.47 1.74 0.19 0.27 1.15 0.91–1.45 1.33 0.25 0.33 1.15 0.91–1.47 1.36 0.24 0.38
ApoC3 0.87 0.69–1.08 1.64 0.20 0.27 0.87 0.69–1.09 1.51 0.22 0.33 0.76 0.57–1.00 3.76 0.52 0.66
ApoE 1.16 0.89–1.50 1.23 0.27 0.31 1.13 0.86–1.49 0.77 0.38 0.43 1.06 0.76–1.46 0.10 0.75 0.75
ApoH 0.76 0.61–0.94 6.26 0.012 0.024 0.77 0.62–0.96 5.50 0.019 0.04 0.74 0.59–0.93 6.90 0.009 0.018
ApoJ 1.06 0.85–1.32 0.29 0.59 0.59 1.08 0.86–1.35 0.44 0.51 0.51 1.07 0.85–1.33 0.31 0.58 0.66
ApoB/ApoA11.60 1.–2.11 10.92 0.001 0.004 1.46 1.09–1.95 6.53 0.011 0.04 1.61 1.18–2.21 8.90 0.003 0.012
Covariates: age, sex, years of education and APOE e4 carrier status. CVD risk index was also included as a covariate in the series of analyses shown on the left side of
table.
"CH, cholesterol; TG, triglycerides; HDL, high density lipoprotein; LDL, low density lipoprotein.
doi:10.1371/journal.pone.0034078.t007
Table 8. Summary of correlations between apolipoproteins and cognitive impairment, cognitive decline and MRI changes over 2
years.
Cognitive
impairment
Cognitive decline over
2 years
MRI lower volume
at Wave 1
MRI volume decrease
over 2 years
ApoA1 - low ++
ApoA2 - low ++
ApoB - high
ApoC3 - high ++
ApoE – high ++
ApoH – low ++
ApoJ - high ++ +
ApoB/ApoA1 high ++ +
+ Significantly indicates relationship in direction of pathology.
doi:10.1371/journal.pone.0034078.t008
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Our results showed that MCI subjects had a lower level of
ApoH in the cross-sectional comparison, and low levels of ApoH
also increased the risk of cognitive decline during follow-up.
ApoH, also known as beta2-glycoprotein I (b2GPI), is a 44 kDa
protein and highly glycosylated [63]. It circulates mainly in free
form although up to 35% is associated with lipoproteins and binds
to negatively charged substances, including heparin, phospholi-
pids, and dextran sulfate. It is the main autoantigen responsible for
negatively charged antiphospholipid antibodies production in the
anti phospholipid syndrome (APS) [64]. ApoH may prevent
activation of the intrinsic blood coagulation cascade by binding to
phospholipids on the surface of damaged cells. High levels of
pathogenic ApoH antibody in turn could cause hypercoagulation
and venous and arterial thrombosis, and is clinically relevant to
APS [65]. APS is a multi-system disorder characterized by
vascular thromboses, neurological complications including vascu-
lar brain disease and increased risk of developing dementia [66].
Furthermore, an interaction between high ApoH antibody levels
and amyloid plaque load in the brain was observed in a transgenic
mouse model (APP695SWE mutation mice immunized with
ApoH) [19].
Our results support current knowledge on the functions of
plasma ApoH. Even though a mechanistic link between plasma
ApoH and cognitive decline has not been established, it may
indicate that subclinical hypercoagulation caused by low ApoH
might increase the risk of cognitive decline.
ApoJ and Cognitive Decline
Our results indicate that ApoJ plasma concentration is raised
early, before AD and dementia symptoms become clinically
evident. We observed that ApoJ levels were negatively correlated
with global cognition and associated with white matter volume
atrophy during follow-up. Apo J is a disulfide linked glycoprotein
composed of two 40 kDa subunits and expressed at higher levels in
the brain than in many other tissues [67,68]. It is associated with
amyloid plaques in vivo [69], has been shown to bind Ab in vitro
[70] and facilitates Ab transport across the BBB [71]. Several
studies have shown increased expression of ApoJ in the brains of
AD patients [72,73]. ApoJ in white matter is increased in aged rat
brain [74]. Recently, two large genome-wide association studies
revealed that the APOJ/clusterin gene is an important suscepti-
bility gene for AD in different populations, in addition to APOE
[39,40]. Two studies demonstrated that the level of ApoJ in CSF is
significantly increased in AD patients [75,76].
We did not find that plasma ApoJ levels were associated with
cognitive decline during follow-up. However, it has been reported
that high plasma ApoJ was associated with clinical progression of
AD [20]. The major difference between that report and our results
is that cognitively normal participants in MAS have only been
followed up for two years and MCI and mild dementia were the
major diagnoses at Wave 2. It would be worthwhile to investigate
whether ApoJ has a causal role in AD or is a contributory factor to
the development or progression of the disease.
We have followed up subjects for only two years, and further
follow-up will be needed to develop a more complete view of the
observed relationship, especially for incident MCI and AD
subjects. Serial measurements may also help determine if
apolipoproteins play a major casual role in MCI and AD. The
findings, moreover, need to be replicated in independent
populations. The examination of transgenic animal models of
AD may also be informative in this regard. The final objective
would be to determine if modification of plasma apolipoprotein
levels can reduce the risk of cognitive disorders in the elderly.
In conclusion, this study indicates that apolipoprotein levels are
dysregulated in the plasma of MCI subjects at an early stage of
cognitive decline, before a clinical diagnosis of AD is possible.
ApoA1, ApoH and ApoJ may be potential clinical biomarkers for
cognitive impairment. Our results provide further support for
a pathophysiological role for these apolipoproteins in cognitive
decline in the elderly, and possibly AD. As early indicators of
cognitive decline, these apolipoproteins might also become targets
of treatment or preventative healthcare measures.
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